Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Hot Topics of the Day|PHGKB
Search PHGKB:


Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
486 hot topic(s) found with the query "Heart disease"

Estimated County-Level Prevalence of Selected Underlying Medical Conditions Associated with Increased Risk for Severe COVID-19 Illness - United States, 2018.
Razzaghi Hilda et al. MMWR. Morbidity and mortality weekly report 2020 Jul (29) 945-950 (Posted: Jul-24-2020 9AM)

The median model-based estimate of the prevalence of any of five underlying medical conditions associated with increased risk for severe COVID-19–associated illness among U.S. adults was 47.2% among 3,142 U.S. counties. The estimated number of persons with these conditions followed population distributions, but prevalence was higher in more rural counties.

Clinical outcomes of a genomic screening program for actionable genetic conditions
AH Buchanan et al, Genetics in Medicine, June 30, 2020 (Posted: Jul-01-2020 8AM)

A study of electronic health records shows that among individuals with variants in tier1 genes (BRCA, Lynch syndrome, familial hypercholesterolemia, 87% did not have a prior genetic diagnosis. Genomic screening programs can identify individuals at increased risk of cancer and heart disease and facilitate risk management and early cancer detection.

Genomic analyses implicate noncoding de novo variants in congenital heart disease
F Richter et al, Nature Genetics, June 29, 2020 (Posted: Jul-01-2020 8AM)

A ‘Cure for Heart Disease’? A Single Shot Succeeds in Monkeys
G Kolata, NY Times, June 27, 2020 (Posted: Jun-29-2020 8AM)

In the first gene-editing experiment of its kind, scientists have disabled two genes in monkeys that raise the risk for heart disease (PCSK9 and LDL). Humans carry the genes as well, and the experiment has raised hopes that a leading killer may one day be tamed.

Could tracking RNA in body fluids reveal disease?
E Dolgin, Nature Outlook, June 17, 2020 (Posted: Jun-22-2020 9AM)

Tests that detect extracellular RNA to spot cancer, heart disease and other conditions are in development. However, heterogeneity of the RNA repertoire can make it difficult to discern clinically useful biomarkers amid the background molecular noise.

Are You at Higher Risk for Severe Illness?
CDC, March 2020 Brand (Posted: Mar-20-2020 0PM)

People who are at higher risk from severe illness Some people may be at higher risk of getting very sick from this illness. This includes: •Older adults •People who have serious underlying medical conditions like: ?Heart disease ?Diabetes ?Lung disease

Heart Disease Family Health History, and Familial Hypercholesterolemia
CDC, March 2020 Brand (Posted: Mar-05-2020 8AM)

Having a family health history of heart disease makes you more likely to develop heart disease yourself. In some cases, having family members with heart disease at a young age (age 50 or younger) can be a sign of familial hypercholesterolemia, a genetic disease that causes high cholesterol. Take time to collect your family health history of heart disease.

Down syndrome.
Antonarakis Stylianos E et al. Nature reviews. Disease primers 2020 Feb (1) 9 (Posted: Feb-27-2020 7AM)

Since the first description of trisomy 21, we have learned much about intellectual disability and genetic risk factors for congenital heart disease. Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored.

Making Informed CHOICES: The Launch of a "Big Data" Pragmatic Trial to Improve Cholesterol Management and Prevent Heart Disease in Ontario.
Ferreira-Legere Laura E et al. Healthcare quarterly (Toronto, Ont.) 2020 Jan 22(4) 6-9 (Posted: Feb-26-2020 8AM)

The study is a pragmatic, registry-based, cluster randomized controlled trial that aims to improve cholesterol management through appropriate statin use in adults and to ultimately reduce cardiovascular events in high-risk communities. It uses an innovative, multicomponent intervention approach that includes audit and feedback reports and educational materials.

Genetic considerations for adults with congenital heart disease.
Ito Seiji et al. American journal of medical genetics. Part C, Seminars in medical genetics 2020 Feb (Posted: Feb-19-2020 9AM)

The population of adults with CHD is growing rapidly with advances in medical care. Genetic causes of CHD can be classified into: (a) chromosomal aneuploidy, (b) large chromosomal deletion or duplication, (c) single gene mutation, and (d) copy number variation. 20-30% of CHD cases have an established etiology. The role of genetics in the field is increasing.

The Cardiac Genome Clinic: implementing genome sequencing in pediatric heart disease
MS Reuter et al, Genetics in Medicine, February 10, 2020 (Posted: Feb-10-2020 9AM)

We analyzed genome sequencing data of 111 families with cardiac lesions for rare, disease-associated variation. In 14 families (12.6%), we identified causative variants: seven were de novo (ANKRD11, KMT2D, NR2F2, POGZ, PTPN11, PURA, SALL1) and six were inherited from parents with no or subclinical heart phenotypes.

Genetics of Congenital Heart Disease.
Williams Kylia et al. Biomolecules 2019 Dec (12) (Posted: Feb-07-2020 8AM)

The genetic workup for structural congenital heart disease.
Jerves Teodoro et al. American journal of medical genetics. Part C, Seminars in medical genetics 2019 Dec (Posted: Feb-07-2020 8AM)

Genetic Contribution to Congenital Heart Disease (CHD).
Shabana N A et al. Pediatric cardiology 2020 Jan (1) 12-23 (Posted: Feb-07-2020 8AM)

The elucidation of genetic components remains difficult because it is a genetically heterogeneous disease. Currently, the major identified genetic causes include chromosomal abnormalities, large subchromosomal deletions/duplications, and point mutations. However, much more remains to be unraveled.

Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging.
Hou Ying-Chen Claire et al. Proceedings of the National Academy of Sciences of the United States of America 2020 Jan (Posted: Jan-29-2020 8AM)

Genome sequencing has established clinical utility for rare disease diagnosis. While increasing numbers of individuals have undergone elective genome sequencing, a comprehensive study surveying genome-wide disease-associated genes in adults with deep phenotyping has not been reported

Does Heart Disease Run in Families? Here's Everything You Need to Know
TG Hope, Better Homes and Garden, January 2020 (Posted: Jan-28-2020 7AM)

Knowing the who, what, when, and whys of your relatives’ heart disease histories helps you best protect your own. The heart health of your first-degree relatives—parents, siblings, children—impacts your own risk the most, especially if they developed heart disease prematurely.

Reducing the Global Public Health Burden of Familial Hypercholesterolemia: More Work Ahead
MJ Khoury et al, CDC Blog, January 21 2020 Brand (Posted: Jan-21-2020 1PM)

Historically, FH has served as a paradigm for the role of cholesterol in heart disease. FH now also serve as a paradigm for bringing together the strengths of both public health and precision medicine approaches to health. The recommendations of this international group highlight the importance of integrating FH care in health systems with a lifelong approach to care

De novo variants in exomes of congenital heart disease patients identify risk genes and pathways.
Sevim Bayrak Cigdem et al. Genome medicine 2020 Jan (1) 9 (Posted: Jan-17-2020 8AM)

'Polygenic' analyses may sharpen disease risk predictions.
Kaiser Jocelyn et al. Science (New York, N.Y.) 2019 12 (6472) 1431 (Posted: Dec-21-2019 4PM)

Recent studies show a woman could receive a more individualized, accurate cancer risk estimate by factoring in other gene variants. A preprint posted last month finds that a person's “polygenic” background influences not only the disease risk conferred by a BRCA1 defect, but also risks from single gene mutations linked to colorectal cancer and heart disease.

Biological age in UK Biobank: biomarker composition and prediction of mortality, coronary heart disease and hospital admissions
MS Chan et al, MedrxIV, December 15, 2019 (Posted: Dec-15-2019 4PM)

This study identified that markers of impaired function in a range of organs account for a substantial proportion of the apparent effect of age on disease and hospital admissions. It supports a broader, multi-system approach to research and prevention of diseases of ageing

Discovery of 318 novel loci for type-2 diabetes and related micro- and macrovascular outcomes among 1.4 million participants in a multi-ethnic meta-analysis.
M Vujkovic et al, BIoRXIV preprints, November 2019 (Posted: Nov-30-2019 10AM)

We investigated the genetic etiology of T2D-related vascular outcomes in the MVP and observed statistical SNP-T2D interactions at 13 variants, including 3 for coronary heart disease, 1 for PAD, 2 for stroke, 4 for retinopathy, 2 for CKD, and 1 for neuropathy.

FH Treatments and Preventing Heart Disease
Youtube video, November 26, 2019 (Posted: Nov-28-2019 9AM)

Katherine Wilemon from the FH Foundation speaks to Dr. Michael Gibson about the opportunities for the diagnosis and treatment of familial hypercholesterolemia. Watch this episode of ClinicalTrialResults from AHA 2019.

Causal relationships between obesity and the leading causes of death in women and men.
Censin Jenny C et al. PLoS genetics 2019 Oct (10) e1008405 (Posted: Nov-16-2019 7AM)

Using mendelian randomization, obesity traits were found to be causally involved in the majority of the leading causes of death, and some obesity traits affect disease risk differently in men and women. This has potential implications for public health strategies and indicates that sex-specific preventative measures may be needed.

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
NA Marston et al, Circulation, November 11, 2019 (Posted: Nov-14-2019 8AM)

This is a study of >14,000 patients with atherosclerotic heart disease from the FOURIER trial. Patients with high polygenic risk, regardless of clinical risk, had a high event rate and derived the greatest relative and absolute benefit from evolocumab, which mitigated this risk.

Family History and Heart Disease
NIDDK podcast, November 11, 2019 (Posted: Nov-12-2019 8AM)

Heart disease is the number one cause of death for men and women. And if you have a family history of heart disease that may put you at a greater risk. Your risk increases if a close relative was diagnosed with heart disease, especially if it was before the age of 55 in your father or brother, or before the age of 65 if it was your mother or a sister.

UVM Health Network to offer DNA testing as part of primary care
K Jickling, Support VTDigger, November 7,y 2019 (Posted: Nov-09-2019 8AM)

The tests are part of a pilot project that will allow primary care doctors and geneticists to identify and treat preventable diseases earlier. Using blood drawn as part of the appointment, the tests will analyze 147 genes for mutations that are linked to certain diseases, such as cancer or heart disease.

A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI.
Claassens Daniel M F et al. The New England journal of medicine 2019 Oct (17) 1621-1631 (Posted: Oct-24-2019 8AM)

In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding.

Looking back and thinking forwards - 15 years of cardiology and cardiovascular research.
Kalman Jonathan M et al. Nature reviews. Cardiology 2019 Sep (Posted: Oct-21-2019 10AM)

Several practice-changing breakthroughs are described, such as those that target risk factors such as inflammation and elevated LDL-cholesterol levels. Furthermore, these key opinion leaders predict that machine learning technology and data derived from wearable devices will pave the way towards the coveted goal of personalized medicine.

Integration of Large-Scale Genomic Data Sources With Evolutionary History Reveals Novel Genetic Loci for Congenital Heart Disease
E Fotieu et al, Circulation Genomics and Precision Medicine, October 2019 (Posted: Oct-19-2019 7AM)

We compared copy number variants present in 4634 nonsyndromic CHD cases derived from publicly available data resources and the literature, and >27?000 healthy individuals. We analyzed deletions and duplications independently and identified copy number variant regions exclusive to cases. These data were integrated with whole-exome sequencing data.

Color Makes Polygenic Scores Available to Participants Through New Study
A Zhou, Color, October 2019 (Posted: Oct-19-2019 7AM)

Researchers have increasingly recognized that most individuals with common diseases such as CAD do not have a rare monogenic mutation. Rather, their inherited risk may be due to the cumulative effect of many variants scattered across the genome. Each of these alone has a small contribution to heart disease risk — but in aggregate they can have a large effect.

Doctors Limit What to Tell Patients About Their DNA Test. Should They?
M Evans et al, Wall Street Journal. October 4, 2019 (Posted: Oct-06-2019 2PM)

The Mayo Clinic is scanning 20,000 genes for thousands of patients to study genes’ role in disease. It will hand over results for just 59. Mayo will look for certain disease-causing gene variants for heart disease or breast cancer, and offer results to patients who have them. But it doesn’t look at variants for early-onset Alzheimer’s or Lou Gehrig’s disease.

Heart Disease and Stroke Map Widget
CDC, 2019 Brand (Posted: Oct-01-2019 8AM)

Deadly condition more common than once thought-Familial hypercholesterolemia raises risk of heart disease, death
K Corso, ABC News, September 30, 2019 (Posted: Oct-01-2019 8AM)

Familial hypercholesterolemia is a genetic problem where the gene for clearing out LDL cholesterol is actually mutated, it's broken, so what happens is LDL cholesterol, the bad cholesterol, builds up in the bloodstream and then causes plaque or atherosclerosis to form. Diet and exercise aren't enough to address FH.

Clinical utility of exome sequencing in infantile heart failure
A Ritter et al, Genetics in Medicine, September 16, 2019 (Posted: Sep-17-2019 7AM)

Dilated cardiomyopathy was the predominant cardiac diagnosis, seen in 60% of patients. A molecular diagnosis was identified in 66.7% of patients (10/15). Of those diagnoses, 70% would not have been detected using multigene next-generation sequencing panels.

Genetics of rheumatic fever and rheumatic heart disease
B Muhamed et al, Nature Rev Cardiology, September 16, 2019 (Posted: Sep-17-2019 7AM)

A combination of risk factors can contribute to increased susceptibility to group A streptococcal infection, rheumatic fever and, ultimately, RHD. The risk of rheumatic fever in an individual with a family history of RHD is nearly fivefold higher than that in an individual with no family history of RHD.

Mothers with long QT syndrome are at increased risk for fetal death: Findings from a multicenter international study.
Cuneo Bettina F et al. American journal of obstetrics and gynecology 2019 Sep (Posted: Sep-16-2019 8AM)

Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association.
Cresci Sharon et al. Circulation. Genomic and precision medicine 2019 Sep HCG0000000000000058 (Posted: Sep-13-2019 10AM)

The goals of this scientific statement are to provide a comprehensive overview of the current state of these omics as they relate to the development and progression of heart failure and to consider the current and potential future applications of these data for precision medicine with respect to prevention, diagnosis, and therapy.

A protocol integrating remote patient monitoring patient reported outcomes and cardiovascular biomarkers
C Shufelt et al, NPJ Digital Medicine, September 3, 2019 (Posted: Sep-03-2019 10AM)

Using biosensor, biomarkers, and patient-reported outcomes in participants with stable ischemic heart disease, the PRE-MACE study is designed to measure cross-sectional correlations and establish the ability of remote monitoring to predict major adverse cardiovascular event.

Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease
B Ference et al JAMA, September 2, 2019 (Posted: Sep-02-2019 6AM)

Mendelian randomization & genetic risk scores in action: Using UK biobank data, this study found that genetic variants associated with lower LDL-C and systolic blood pressure are associated with lower lifetime risk of cardiovascular disease.

Association of Multifaceted Mobile Technology–Enabled Primary Care Intervention With Cardiovascular Disease Risk Management in Rural Indonesia
A Patel et al, JAMA Cardiology, August 2019 (Posted: Aug-29-2019 8AM)

Use of polygenic risk scores and other molecular markers to enhance cardiovascular risk prediction: prospective cohort study and modelling analysis
L Sun et al, BioRXIV, August 2019 (Posted: Aug-24-2019 4PM)

Adding information on both PRS and selected biochemistry markers moderately enhanced CVD predictive accuracy and could improve primary prevention of CVD. However, our modelling suggested that targeted assessment of molecular markers among individuals at intermediate-risk would be more efficient than blanket approaches.

Prevalence and clinical importance of titin truncating variants in adults without known congestive heart failure
JP Pirruccello et al, MedRXIV, August 2019 (Posted: Aug-23-2019 8AM)

Cross-sectional studies of various forms of dilated cardiomyopathy have noted a truncating mutation in the gene encoding titin ('TTNtv') in 7-30% of patients, but the clinical importance of identifying a TTNtv in an asymptomatic adult is largely unknown.

Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis.
Akioyamen Leo E et al. Angiology 2019 Sep 70(8) 726-736 (Posted: Aug-21-2019 8AM)

Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder predisposing affected individuals to lifelong low-density lipoprotein cholesterol (LDL-C) elevation and coronary heart disease. However, whether HeFH increases the risk of peripheral arterial disease (PAD) and ischemic stroke is undetermined.

Beyond the One Gene-One Disease Paradigm: Complex Genetics and Pleiotropy in Inheritable Cardiac Disorders
Cerrone Marina et al. Circulation 2019 08 (7) 595-610 (Posted: Aug-17-2019 9AM)

Inheritable cardiac disorders are often associated with increased risk of sudden death in the young. In recent years, through genotype-phenotype studies and methodological advances in genetics, it has become evident that most inheritable cardiac disorders are not monogenic but, rather, have a complex genetic basis.

Risk Prediction Model in Children With Hypertrophic Cardiomyopathy: A Work in Progress.
Bonow Robert O et al. JAMA cardiology 2019 Aug (Posted: Aug-15-2019 8AM)

Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids).
Norrish Gabrielle et al. JAMA cardiology 2019 Aug (Posted: Aug-15-2019 8AM)

Sudden cardiac death (SCD) is the most common mode of death in childhood hypertrophic cardiomyopathy (HCM), but there is no validated algorithm to identify those at highest risk. The study provides a new, validated risk stratification model for SCD in childhood HCM that can provide individualized estimates of risk at 5 years using available clinical risk factors.

Cardiac Evaluation of Children With a Family History of Sudden Death.
Webster Gregory et al. Journal of the American College of Cardiology 2019 Aug 74(6) 759-770 (Posted: Aug-14-2019 8AM)

After sudden death occurs in the young, first-degree family members should undergo clinical screening for occult cardiac disease, but the diagnostic yield from screening is not well-defined in the United States.This study determined the clinical predictors of cardiac diagnosis in children referred for evaluation following a sudden death in the family.

Assessing the barriers to cardiac care in carriers of Duchenne and Becker muscular dystrophy.
Eekhoff Lauren et al. Journal of genetic counseling 2019 Aug (Posted: Aug-07-2019 8AM)

A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes.
Park Joseph et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Aug (Posted: Aug-07-2019 7AM)

Is Genetic Testing for Heart Disease Right for Me?
Moscarello Tia et al. JAMA cardiology 2019 Jul (Posted: Aug-02-2019 8AM)

Heart disease is a leading cause of death worldwide and often runs in families. Certain heart conditions are caused by a single harmful DNA mutation while others are caused by the combined effect of many smaller-impact DNA variations. Tests for genetic conditions can be ordered by cardiologists and genetic counselors, and can help patients and their families.

Association of APOL1 Risk Alleles with Cardiovascular Disease in African Americans in the Million Veteran Program.
Bick Alexander G et al. Circulation 2019 Jul (Posted: Jul-30-2019 8AM)

13% of African-Americans carry two copies of the APOL1 risk alleles, which are associated with increased risk of chronic kidney disease. The study We sought to test the association of APOL1 G1/G2 alleles with coronary artery disease (CAD), peripheral artery disease (PAD), and stroke among African American individuals in the Million Veteran Program (MVP).

Individuals Had More Heart Attacks and Strokes if Cardiovascular Prescription Rejected or Unfilled
The FH Foundation, July 23, 2019 (Posted: Jul-23-2019 3PM)

Individuals with familial hypercholesterolemia, established heart disease, or extremely high risk of heart disease were found to have more cardiovascular events when PCSK9 inhibitor prescriptions were rejected or unfilled. The study analyzed almost 140,000 adults from 2015 to 2017.

Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
Martin Jesse et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Jul (Posted: Jul-19-2019 8AM)

The frequency of escalation (clopidogrel switched to prasugrel/ticagrelor) and de-escalation (prasugrel/ticagrelor switched to clopidogrel) was evaluated in 1063 PCI patients who underwent CYP2C19 genotyping. The study found that CYP2C19-guided escalation and de-escalation is common in a real-world setting. Continuation of clopidogrel in nonfunctional allele carriers is associated with adverse outcomes.

Get familiar with your family health history,
Fox 16, July 15, 2019 (Posted: Jul-17-2019 8AM)

If a relative had diabetes, heart disease or cancer, that doesnâ??t mean youâ??ll definitely get it too. Other things besides genesâ??like our health habits and environmentâ??matter as well. But itâ??s better to know if thereâ??s a chance you may be at higher risk. That way, you can take steps to lower your risk or find the condition early, when it may be easier to treat. For example, if certain diseases run in your family, your doctor may want you to get screened for them earlier or more often than usual.

Making The Case For Cascade Screening Amongst Families With Inherited Heart Diseases.
Ingles Jodie et al. Heart rhythm 2019 Jul (Posted: Jul-17-2019 8AM)

Prevalence and Cardiovascular Health Impact of Family History of Premature Heart Disease in the United States: Analysis of the National Health and Nutrition Examination Survey, 2007–2014
Mooneshinghe R, et al. Journal of the American Heart Association. 2019;8 (Posted: Jul-15-2019 9AM)

This CDC paper used population based nationally representative data to estimate the prevalence and public health impact of family history of premature heart disease (under age 50 years). The study shows that family history is common affecting millions of people, and is associated with higher prevalence of heart disease and modifiable heart disease risk factors.

Familial Hypercholesterolemia: What Is It and Who Gets It?
By Jessica Mao, M.D., Erin Michos, M.D., M.H.S., Vasanth Sathiyakumar, M.D., Cat Davis Ahmed, and Seth Martin, M.D., U.S. News, July 11, 2019 (Posted: Jul-12-2019 8AM)

Familial Hypercholesterolemia is a life threatening genetic conviction affecting 1 in 250 people. FH causes 1 in 5 heart attacks under age 45. If diagnosed early, the risk of heart disease can be markedly reduced. Most FH cases are not diagnosed. FH can be diagnosed based on family history and a lipid panel blood test. Genetic testing is available and can be offered to confirm diagnosis and aid in family screening.

Systolic Blood Pressure and Risk of Valvular Heart Disease- A Mendelian Randomization Study
M Nazarzadeh et al, JAMA Cardiology, July 10, 2019 (Posted: Jul-11-2019 8AM)

In this mendelian randomization study of 329 237 individuals, genetically associated 20?mm Hg increments of elevated systolic blood pressure was associated with a higher risk of aortic stenosis, aortic regurgitation, and mitral regurgitation.

Blood samples reveal valuable data — and life-changing surprises for donors
PD McCluskey, Boston Globe, July 5, 2019 (Posted: Jul-09-2019 10AM)

More than 103,000 patients have agreed to provide blood to the Partners HealthCare Biobank, and their samples are providing valuable data for some 200 studies about Alzheimer?s, depression, diabetes, epilepsy, heart disease, and other conditions. But the research initiative is also having another impact, one that is more personal and immediate: It?s revealing genetic red flags that patients otherwise might never have seen.

Variability in aspirin efficacy: all in the genes?
Baigent Colin et al. European heart journal 2019 Jul (Posted: Jul-08-2019 3PM)

This is an editorial about the recent paper: ?Genetic variation at the coronary artery disease locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.? Given the difficulty of selecting healthy individuals for aspirin use for primary prevention, it is of interest to consider whether subgroups defined by genetic variation might offer an alternative method of selecting people in whom the benefits of aspirin greatly exceed the bleeding risks.

Cardiovascular genomics and sudden cardiac death in the young.
Isbister Julia et al. Australian journal of general practice 2019 Mar 48(3) 90-95 (Posted: Jul-02-2019 9AM)

Sudden cardiac death in the young is a rare consequence of a number of genetic cardiovascular disorders. The care of survivors of cardiac arrest and families affected by SCD seeks to prevent further SCD events through family screening. The aim of this article is to review the genetic basis of SCD in the young and outline the clinical aspects of caring for families affected by SCD. Inherited cardiomyopathies and primary arrhythmia syndromes are important causes of SCD in young people.

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality
M O'Riordan, TCMD Heart Disease, June 5, 2019 (Posted: Jun-10-2019 3PM)

Family History-Wide Association Study ("FamWAS") for Identifying Clinical and Environmental Risk Factors for Common Chronic Diseases.
Rasooly Danielle et al. American journal of epidemiology 2019 Jun (Posted: Jun-10-2019 11AM)

Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia.
Wang Xu et al. Lipids in health and disease 2019 Jun 18(1) 131 (Posted: Jun-05-2019 10AM)

Genetic basis of hypertrophic cardiomyopathy in children.
Rupp Stefan et al. Clinical research in cardiology : official journal of the German Cardiac Society 2019 Mar 108(3) 282-289 (Posted: Jun-05-2019 10AM)

2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline.
Grundy Scott M et al. Annals of internal medicine 2019 May (Posted: May-31-2019 10AM)

Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification.
Perrot Nicolas et al. JAMA cardiology 2019 May (Posted: May-31-2019 10AM)

P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Povsic Thomas J et al. JAMA cardiology 2019 May (Posted: May-31-2019 10AM)

Dilated Cardiomyopathy - From Epidemiologic to Genetic Phenotypes A Translational Review of Current Literature.
Reichart Daniel et al. Journal of internal medicine 2019 May (Posted: May-29-2019 8AM)

Sudden Cardiac Death Risk in Hypertrophic Cardiomyopathy: Wither Our Cognitive Miser.
Ommen Steve R et al. JAMA cardiology 2019 May (Posted: May-27-2019 5PM)

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
Maron Martin S et al. JAMA cardiology 2019 May (Posted: May-27-2019 5PM)

Using a genetic risk score to calculate the optimal age for an individual to undergo coronary artery calcium screening.
Severance Lauren M et al. Journal of cardiovascular computed tomography 2019 May (Posted: May-22-2019 8AM)

Using Genetics to Plan Future Randomized Trials of Lipoprotein(a) Lowering-How Much Reduction, for How Long, and in Whom?
Thanassoulis George et al. JAMA cardiology 2019 Apr (Posted: May-20-2019 9AM)

Rare Gene Mutations May Prevent Heart Disease
Boston University, May 10, 2019 (Posted: May-14-2019 2PM)

Inherited cardiomyopathies.
Miles Chris et al. BMJ (Clinical research ed.) 2019 05 l1570 (Posted: May-08-2019 3PM)

Polygenic risk scores in coronary artery disease.
Rao Abhiram S et al. Current opinion in cardiology 2019 Apr (Posted: Apr-24-2019 7AM)

VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia.
Miramontes-González José Pablo et al. Atherosclerosis 2019 Mar 28517-22 (Posted: Apr-24-2019 7AM)

Usefulness of Genetic Testing in Sudden Cardiac Arrest Survivors With or Without Previous Clinical Evidence of Heart Disease.
Asatryan Babken et al. The American journal of cardiology 2019 Mar (Posted: Apr-17-2019 9AM)

Effect of communicating phenotypic and genetic risk of coronary heart disease alongside web-based lifestyle advice: the INFORM Randomised Controlled Trial.
Silarova Barbora et al. Heart (British Cardiac Society) 2019 Mar (Posted: Apr-02-2019 9AM)

Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease
H Naci et al, NPJ Digital Medicine, March 2019 (Posted: Mar-25-2019 10AM)

Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort.
Khandaker Golam M et al. Molecular psychiatry 2019 Mar (Posted: Mar-21-2019 8AM)

Biology, Genetics and Heart Disease
The FH Foundation, March 14, 2019 (Posted: Mar-14-2019 0PM)

O Dikilitas et al, JACC, March 2019 (Posted: Mar-06-2019 8AM)

Myocardial Infarction in Young Women.
Vaccarino Viola et al. Circulation 2019 Feb (8) 1057-1059 (Posted: Feb-22-2019 9AM)

How to identify familial premature myocardial infarction: comparing approaches to identify familial hypercholesterolemia.
Beheshti Sabina et al. The Journal of clinical endocrinology and metabolism 2019 Feb (Posted: Feb-20-2019 11AM)

Actions in Support of Newborn Screening for Critical Congenital Heart Disease — United States, 2011–2018
CDC MMWR, February 7, 2019 Brand (Posted: Feb-07-2019 2PM)

Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association.
Pierpont Mary Ella et al. Circulation 2018 Nov (21) e653-e711 (Posted: Feb-04-2019 1PM)

Application of next-generation sequencing for the diagnosis of fetuses with congenital heart defects.
Qiao Fengchang et al. Current opinion in obstetrics & gynecology 2019 Jan (Posted: Feb-04-2019 1PM)

What genetics could mean for your heart disease risk — and what you can do about it
K Musunuru etal, Philadelphia Inquirer, February 1, 2019 (Posted: Feb-01-2019 11AM)

Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes.
Ingles Jodie et al. Circulation. Genomic and precision medicine 2019 Jan (Posted: Jan-30-2019 9AM)

Association of Thyroid Function Genetic Predictors With Atrial Fibrillation: A Phenome-Wide Association Study and Inverse-Variance Weighted Average Meta-analysis.
Salem Joe-Elie et al. JAMA cardiology 2019 Jan (Posted: Jan-25-2019 10AM)

Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH.
Santos Raul D et al. Atherosclerosis 2018 Dec (Posted: Jan-23-2019 2PM)

Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction.
Cui Yuxia et al. Clinical cardiology 2019 Jan (Posted: Jan-23-2019 2PM)

Value of genetic testing in the prevention of coronary heart disease events
Y Hynninen et al, PLOS One, January 2019 (Posted: Jan-20-2019 8AM)

Hypertension genetic risk score is associated with burden of coronary heart disease among patients referred for coronary angiography.
Lukács Krogager Maria et al. PloS one 2018 13(12) e0208645 (Posted: Jan-02-2019 4PM)

Fetal congenital heart disease: Associated anomalies, identification of genetic anomalies by single-nucleotide polymorphism array analysis, and postnatal outcome.
Cai Meiying et al. Medicine 2018 Dec 97(50) e13617 (Posted: Jan-02-2019 4PM)

Is Heart Disease Genetic?
L Meyers, Genome Medical, December 2018 (Posted: Dec-30-2018 9AM)

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018.
Brunham Liam R et al. The Canadian journal of cardiology 2018 Dec 34(12) 1553-1563 (Posted: Dec-19-2018 10AM)

Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease.
Cao Ye-Xuan et al. Journal of translational medicine 2018 Dec 16(1) 345 (Posted: Dec-19-2018 10AM)

Vascular endothelial growth factor gene transfer therapy for coronary artery disease: A systematic review and meta-analysis.
Yuan Rong et al. Cardiovascular therapeutics 2018 Oct 36(5) e12461 (Posted: Dec-19-2018 10AM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.